PureTech Market Capitalization from 2010 to 2024

PRTC Stock  USD 21.24  0.83  3.76%   
PureTech Health's Market Cap is increasing over the years with stable fluctuation. Market Cap is expected to dwindle to about 739.7 M.
Check PureTech Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PureTech Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7 M, Interest Expense of 14.2 M or Selling General Administrative of 26.9 M, as well as many indicators such as Price To Sales Ratio of 222, Dividend Yield of 0.0 or PTB Ratio of 1.76. PureTech financial statements analysis is a perfect complement when working with PureTech Health Valuation or Volatility modules.
  
Check out the analysis of PureTech Health Correlation against competitors.

Latest PureTech Health's Market Capitalization Growth Pattern

Below is the plot of the Market Cap of PureTech Health PLC over the last few years. It is PureTech Health's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PureTech Health's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 528.4 M10 Years Trend
Pretty Stable
   Market Cap   
       Timeline  

PureTech Market Capitalization Regression Statistics

Arithmetic Mean6,146,569,254
Geometric Mean4,480,727,906
Coefficient Of Variation64.79
Mean Deviation3,721,899,129
Median8,923,897,336
Standard Deviation3,982,198,013
Sample Variance15857901T
Range10.5B
R-Value0.23
Mean Square Error16182724.8T
R-Squared0.05
Significance0.41
Slope203,848,609
Total Sum of Squares222010614.2T

PureTech Market Capitalization History

2024739.7 M
2023778.6 M
20208.9 B
201811.3 B
20159.3 B
20133.1 B

About PureTech Health Financial Statements

PureTech Health stakeholders use historical fundamental indicators, such as PureTech Health's Market Capitalization, to determine how well the company is positioned to perform in the future. Although PureTech Health investors may analyze each financial statement separately, they are all interrelated. For example, changes in PureTech Health's assets and liabilities are reflected in the revenues and expenses on PureTech Health's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PureTech Health PLC. Please read more on our technical analysis and fundamental analysis pages.
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PureTech Health operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 95 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether PureTech Health PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PureTech Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puretech Health Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puretech Health Plc Stock:
Check out the analysis of PureTech Health Correlation against competitors.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PureTech Health. If investors know PureTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PureTech Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.615
Earnings Share
(3.00)
Revenue Per Share
0.02
Quarterly Revenue Growth
(0.91)
Return On Assets
(0.13)
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PureTech Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if PureTech Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PureTech Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.